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Clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases
(RGNs) are highly efficient genome editing tools.1–3 CRISPR-associated 9 (Cas9) RGNs are
directed to genomic loci by guide RNAs (gRNAs) containing 20 nucleotides that are
complementary to a target DNA sequence. However, RGNs can induce mutations at sites
that differ by as many as five nucleotides from the intended target4–6. Here we report that
truncated gRNAs, with shorter regions of target complementarity <20 nucleotides in length,
can decrease undesired mutagenesis at off-target sites by as much as 5000-fold or more
without sacrificing on-target genome editing efficiencies. In addition, combining truncated
gRNAs with pairs of Cas9 variants that nick DNA (paired nickases) can lead to further
reductions in off-target mutations. Our results delineate a simple, effective strategy to
improve the specificities of Cas9 nucleases or paired nickases.
The Streptococcus pyogenes Cas9 nuclease (hereafter referred to as Cas9) can robustly
induce insertion or deletion mutations (indels) or precise alterations via repair of Cas9-
induced double-stranded breaks (DSBs) by non-homologous end-joining (NHEJ) or
homology-directed repair (HDR), respectively. However, unwanted indel mutations can also
be induced at off-target sites sharing sequence similarity to the on-target site4–6. Recently,
several approaches to improve the specificity of RNA-guided Cas9 have been recently
described including truncation of the 3' end of gRNA (which is derived from the tracrRNA
domain that is believed to mediate interaction with Cas9) or addition of two G nucleotides to
the 5' end of the gRNA (just before the 20 nt complementarity region); however, RGNs
utilizing these altered gRNAs show decreased on-target activities6, 7. Alternatively, a
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nickases8), in which two gRNAs targeted to adjacent sites on opposite DNA strands each
recruit a Cas9 variant (Cas9-D10A) that nicks DNA instead of cutting both strands7, 9, 10,
can reduce mutation frequencies at known off-target sites of single gRNA-guided Cas9
nuclease in human cells7, 10. Nevertheless, indel mutations can still be observed at some off-
target sites10 and the addition of a second gRNA might introduce new off-target mutations
because a single gRNA-directed Cas9 nickase can efficiently induce indels at some
sites7, 9, 11. In addition, the need to express appropriately positioned and oriented paired
gRNAs presents technical challenges if implemented with multiplex12–14 or genome-wide
library-based applications of RGNs15, 16. Finally, the paired nickase strategy cannot be used
to improve the specificities of catalytically inactive Cas9 (dCas9) fused to heterologous
effectors, such as transcriptional activation domains17–19. Thus, the development of
additional methods to improve the specificity of CRISPR-based systems remains an
important priority.
We hypothesized that off-target effects of RGNs might be minimized by decreasing the
length of the gRNA-DNA interface. Such an approach might seem counterintuitive, but
we20 and others7, 10 have shown that lengthening the 5' end of the complementary region
can reduce on-target editing efficiency, with some of these longer gRNAs processed back to
standard length in human cells10. In contrast, certain gRNAs bearing either truncations or
progressively greater numbers of mismatches at the 5' end of their complementarity
targeting regions have been shown to retain robust Cas9-mediated on-target cleavage
activities4, 9, 21. We hypothesized that these 5'-end nucleotides might not be necessary for
full gRNA activity and that these nucleotides might normally compensate for mismatches at
other positions along the gRNA-target DNA interface; therefore, we reasoned that shorter
gRNAs might be more sensitive to mismatches and thus more specific (Supplementary Fig.
1).
To test our predictions, we constructed a series of progressively shorter gRNAs for a target
site in the EGFP reporter gene containing 15, 17, 19, and 20 complementary nucleotides
(Online Methods and Fig. 1a). We measured the abilities of these gRNAs to direct Cas9-
induced indels at this target site in human U2OS.EGFP cells by quantifying mutation of a
single integrated and constitutively expressed EGFP gene 4, 22 (Online Methods). gRNAs
that have 17 or 19 nucleotides of target complementarity showed activities comparable to
the full-length gRNA with 20 nucleotides of complementarity, whereas a gRNA containing
15 nucleotides of complementarity failed to show activity (Fig. 1b). To extend the generality
of these findings, we assayed full-length gRNAs and matched gRNAs with 18, 17 and/or 16
nucleotides of complementarity to four additional EGFP reporter gene sites (EGFP sites #1,
#2, #3 and #4; Fig. 1c). For all four target sites, gRNAs with 17 and/or 18 nucleotides of
complementarity functioned as efficiently as (or, in one case, more efficiently than) their
matched full-length counterparts (Fig. 1c). gRNAs with only 16 nucleotides of
complementarity showed substantially decreased or undetectable activities at the two sites
for which they could be made (Fig. 1c). Given these results, in this report we refer to
truncated gRNAs with complementarity lengths of 17 or 18 nucleotides as “trugRNAs” and
RGNs using these tru-gRNAs as “tru-RGNs”.
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tTo determine whether tru-RGNs could efficiently edit endogenous genes, we constructed
trugRNAs for seven sites in three human genes (VEGFA, EMX1, and CLTA), including four
sites targeted in previous studies4–6, 10(Fig. 1d). Five of these seven tru-gRNAs induced
Cas9-mediated indel mutations with efficiencies comparable to those mediated by matched
standard length RGNs (Fig. 1d) (Online Methods) with the two tru-gRNAs that showed
lower activities than their full-length counterparts still exhibiting high absolute rates of
mutagenesis (means of 13.3% and 16.6%) (Fig. 1d). Sanger sequencing confirmed that
indels introduced by tru-RGNs originate at the expected site of cleavage and are essentially
indistinguishable from those induced by their standard counterpart RGNs (Supplementary
Fig. 2). We also found that tru-gRNAs containing a mismatched 5' G and 17 nucleotides of
complementarity could efficiently direct Cas9-induced indels, whereas those bearing a
mismatched 5' G and 16 nucleotides of complementarity showed lower or undetectable
activities compared with matched full-length gRNAs (Supplementary Fig. 3), consistent
with our results that a minimum of 17 nucleotide of complementarity is required for efficient
RGN activity. Finally, we tested whether tru-RGNs could introduce a BamHI restriction site
insertion via HDR with ssODNs and found that they did so for two sites in the VEGFA and
EMX1 genes with efficiencies comparable to or higher than matched standard RGNs (Fig.
1e). We conclude that tru-RGNs can function efficiently to introduce on-target indels or
HDR-mediated genome editing events in human cells.
To assess the specificities of tru-RGNs, we first tested whether they possess greater
sensitivity to Watson-Crick mismatches at the gRNA-DNA interface by testing variants of
the full-length and trugRNAs we had previously made for EGFP sites #1, #2 and #3 (Fig. 1c
above). These variant gRNAs harbor single substitutions or adjacent double substitutions at
each position within the complementarity region (except the 5' G) (Fig. 2a and 2b). Using
the EGFP disruption assay in human U2OS.EGFP cells, we found that tru-RGNs were
generally more sensitive to single and adjacent double mismatches than standard RGNs
(compare bottom and top panels of Fig. 2a and 2b). Magnitudes of sensitivity to mismatches
were site-dependent, with tru-RGNs to EGFP site #1 exhibiting less sensitivity to single and
double mismatches than tru-RGNs to EGFP sites #2 and #3. Note that EGFP site #1 tru-
gRNAs have 18 complementary nucleotides whereas the others have 17.
We next examined whether tru-RGNs have reduced genomic off-target effects in human
cells by using matched full-length and tru-gRNAs targeted to VEGFA site 1, VEGFA site
3,and EMX1 site 1 (Fig. 1d). We chose these target sites because previous studies had
defined a total of 13 off-target sites for the full-length gRNAs targeted to these
sequences4, 5. tru-RGNs exhibited substantially reduced mutagenesis activity relative to
matched standard RGNs at all 13 previously identified off-target sites in human
U2OS.EGFP cells (Table 1), with 11 sites having mutation frequencies below the reliable
detection limit (2 – 5%) of the T7 Endonuclease I (T7EI) assay used for these experiments
(Table 1; Online Methods). We also observed similar results in a different human cell line
(FT-HEK293 cells) (Supplementary Table 1). To enable more sensitive detection of off-
target mutations, we used high-throughput sequencing to assess 12 of the 13 off-target sites
we had analyzed by T7EI assay (for technical reasons, we were unable to amplify the
required shorter amplicon for one of the sites) as well as an additional, previously identified5
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toff-target site for EMX1 site 1 in U2OS.EGFP cells (Fig. 2c). These sequencing results
showed that tru-RGNs induced substantially decreased mutagenesis frequencies at all 13 off-
target sites relative to matched standard RGNs (Fig. 2c and Supplementary Table 2), with
some sites showing decreases of ~5000-fold or more (Fig. 2d). No indel mutations were
observed with RGNs for off-target sites (OT1–4 and OT1–11). Therefore, for these two
sites, we conservatively estimated a likely upper boundary for the average indel frequencies
and calculated a minimum improvement in tru-RGN specificities for these sites of >10,000
or more over standard RGNs (Online Methods; Fig. 2d).
We then sought to assess whether tru-RGNs might induce additional off-target mutations in
the human genome beyond those previously identified for matched full-length RGNs. Based
on the results of our EGFP disruption assay, we reasoned that genomic sites with the fewest
mismatches compared to the on-target site would be the most likely to be mutated.
Therefore, we computationally identified sites in the human genome with one, two or three
mismatches relative to tru-gRNAs targeted to VEGFA site 1, VEFGA site 3 and EMX1 site 1
(Supplementary Table 3a), excluding known off-target sites that had already been examined
by deep sequencing above (Supplementary Table 3b). We used the T7EI assay to examine
97 potential off-target sites including all with one mismatch and either all or some with two
or three mismatches (Supplementary Table 3c and Supplementary Table 4). Only one of
these 97 sites showed detectable levels of indel mutations by T7EI assay in human
U2OS.EGFP cells and none showed detectable indels in human FT-HEK293 cells
(Supplementary Table 4). The one site for which indels were observed was also mutated by
the corresponding standard full-length RGN (Supplementary Results and Supplementary
Fig. 4), demonstrating that this off-target site is not unique to the tru-RGN. We also used
deep sequencing to examine 30 of the most closely matched potential off-target sites
(including all sites with one mismatch for all three RGNs and nearly all sites with two
mismatches for the RGNs targeted to VEGFA Site #1 and EMX1 Site #1 (Supplementary
Table 4d)) and found undetectable or very low rates of indel mutations (Supplementary
Table 5), comparable to those induced by tru-RGNs for other previously known off-target
sites (Supplementary Table 2). Of note, the percentage of sites with mutation rates above
0.1% decreases with increasing numbers of mismatches (Supplementary Table 4e),
validating our focus on sites with fewest mismatches. tru-RGNs generally appear to induce
either very low or undetectable levels of mutations at potential off-target sites that differ by
one or two mismatches; by contrast, our previous study using standard RGNs showed high
levels of mutations at numerous off-target sites bearing up to four or five mismatches4.
Because neither tru-gRNAs nor paired nickases completely eliminate off-target effects, we
explored whether combining these strategies might further reduce such mutations. First, we
used a pair of gRNAs targeted to sites in the human VEGFA gene (VEGFA site 1 and
VEGFA site 4; Fig. 2e) previously shown to work with the paired Cas9-D10A nickase
approach10. Substitution of the full-length gRNA for VEGFA Site #1 with a tru-gRNA did
not adversely affect the induction of indels (Fig. 2f) or incorporation of a restriction site
sequence by HDR (Fig. 2g). We next used deep sequencing to examine mutation frequencies
at four previously validated off-target sites of the VEGFA site 1 gRNA and found that
mutation rates dropped below the detection limit of the sequencing assay at all four of these
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toff-target sites when using paired nickases with one full-length gRNA and one tru-gRNA
(Supplementary Table 6). By contrast, both a single tru-RGN (Supplementary Table 2) and
paired nickases with full-length gRNAs (Supplementary Table 6) still induced off-target
mutations at one of these four off-target sites (OT1–3). Although we substituted a tru-gRNA
for only one of the two full-length gRNAs in our VEGFA paired nickase experiments, we
have shown at another locus (in the EMX1 gene) that use of two tru-gRNAs with Cas9
nickase can robustly induce indels at an endogenous human gene locus (Supplementary Fig.
5). Taken together, we conclude that tru-gRNAs can further reduce the off-target effects of
paired Cas9 nickases (and vice versa) without compromising the efficiency of on-target
genome editing.
Our results show that tru-RGNs can generally introduce mutations via NHEJ or HDR at on-
target sites with high efficiencies and show reduced mutagenic effects at closely matched
off-target sites. One potential model to explain our overall results is that standard RGNs
with full-length gRNAs might possess more affinity for their target sites than is required
(perhaps not unsurprisingly because it might be beneficial for naturally occurring CRISPR
systems to tolerate the introduction of alterations in the target sequence) and that truncation
of the gRNA might poise the tru-RGN/DNA complex to be more sensitive to mismatches,
perhaps by reducing binding energy at the gRNA/DNA interface. The concept of excess
affinity affecting the specificity of DNA binding domains has previously been suggested by
others for engineered zinc finger proteins23, 24.
The use of tru-gRNAs for improving CRISPR specificity offers important advantages over
the paired Cas9 nickase strategy. tru-gRNAs should be technically simpler to implement
with applications involving multiplex12–14 or genome-wide libraries of gRNAs15, 16 and,
unlike the paired nickase strategy, can also be used to improve the specificities of dCas925
or dCas9 fusions to heterologous effector domains such as transcriptional regulatory
domains17–19. In this regard, we note that we have found that tru-gRNAs can efficiently
recruit dCas9-VP64 transcriptional activators to an endogenous human gene (Y.F., V.M.C.,
and J.K.J., unpublished data). tru-RGNs also avoid the need to use a second gRNA that on
its own can potentially induce additional unwanted mutations with a Cas9 nickase. For
example, consistent with previously published results7, 9, 11, we found that a single gRNA to
VEGFA site 4 was capable of efficiently inducing indel mutations with Cas9 nickases (red
bar, Fig. 2f).
Our findings have several important implications for how to choose potential RGN target
sites. The use of shorter gRNAs does not decrease the targeting range of the platform
because target sites with 17 or 18 nts of complementarity will each occur in random DNA
with frequencies equal to those with 20 nts of complementarity. Our results show that tru-
gRGNs generally appear to induce very low or undetectable levels of mutagenesis at off-
target sites with as few as one or two mismatches and suggest that sites with three or more
mismatches will not have mutations at high frequencies, if at all. Thus, a reasonable strategy
for choosing target sites to minimize off-target effects might be to choose tru-gRNA target
sites that are unique in the genome and that have the smallest possible number of potential
off-target sites with 1 or 2 mistmatches. We have modified our web-based ZiFiT Targeter
program26, 27 so that it can identify tru-gRNA sites with 17 or 18 nts of complementarity
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tand provide the user with information about potential off-target sites that differ by 0, 1 or 2
positions in the published genomes of fruit flies, roundworm, zebrafish, mice, rats, humans
using the Bowtie program28. This modified version of ZiFiT is currently accessible at http://
zifit.partners.org.
Our results raise several important questions to be addressed in future experiments.
Although we found that tru-gRNAs with 17 or 18 nts of complementarity generally function
efficiently at the intended target site and have improved specificities, it is possible that
certain gRNAs with shorter and longer complementarity lengths might also possess such
properties. Testing of greater numbers of truncated gRNAs in future experiments should
help to determine this and also whether certain characteristics such as GC content might
predict activity levels. In addition, we presume our tru-gRNAs are generally being expressed
at the same levels as their full-length counterparts because they show comparable activities
and because titration experiments performed for EGFP sites #1, #2, and #3 in which the
amounts of gRNA and Cas9 expression vectors are varied demonstrate that shortened
gRNAs give activity curves similar to their full-length counterparts (Supplementary Fig. 6);
however, more direct, quantitative assessments of tru-gRNA expression levels will be
required to definitively establish this and to better understand why and how tru-gRNAs
function with high efficiencies and specificities.
In summary, tru-gRNAs provide a simple and flexible approach to minimize the off-target
effects of individual Cas9 nucleases, paired Cas9 nickases and, potentially, dCas9 fusion
proteins in human cells. However, we note that definitive assessment of the relative
efficacies of any platform designed to improve specificities will require the development of
an unbiased approach for globally assessing off-target effects in human cells. Continued
efforts to develop methods for assessing and improving specificity will further accelerate the
use of CRISPR-based reagents for research and therapeutic applications.
Online Methods
Plasmid construction
All gRNA expression plasmids were assembled by designing, synthesizing, annealing, and
cloning pairs of oligonucleotides (IDT) harboring the complementarity region into plasmid
pMLM3636 (available from Addgene; http://www.addgene.org/crispr-cas) as previously
described4. The resulting gRNA expression vectors encode a ~100 nt gRNA whose
expression is driven by a human U6 promoter. The sequences of all oligonucleotides used to
construct gRNA expression vectors are shown in Supplementary Table 7. The Cas9 D10A
nickase expression plasmid (pJDS271) bearing a mutation in the RuvC endonuclease
domain was generated by mutating plasmid pJDS246 using a QuikChange kit (Agilent
Technologies) with the following primers: Cas9 D10A sense primer 5'-
tggataaaaagtattctattggtttagccatcggcactaattccg-3'; Cas9 D10A antisense primer 5'-
cggaattagtgccgatggctaaaccaatagaatactttttatcca-3'. All the targeted gRNA plasmids and the
Cas9 nickase plasmids used in this study will be made available through the non-profit
plasmid distribution service Addgene.
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U2OS.EGFP cells harboring a single-copy, integrated EGFP-PEST gene reporter have been
previously described22. These cells were maintained in Advanced DMEM (Life
Technologies) supplemented with 10% FBS, 2 mM GlutaMax (Life Technologies),
penicillin/streptomycin and 400 μg/ml G418. To assay for disruption of EGFP expression, 2
× 105 U2OS.EGFP cells were transfected in duplicate with gRNA expression plasmid or an
empty U6 promoter plasmid as a negative control, Cas9 expression plasmid (pJDS246)4, and
10 ng of td-Tomato expression plasmid (to control for transfection efficiency) using a
LONZA 4D-Nucleofector™, with SE solution and DN100 program according to the
manufacturer's instructions. We used 25 ng/250 ng, 250 ng/750 ng, 200 ng/750 ng, and 250
ng/750 ng of gRNA expression plasmid/Cas9 expression plasmid for experiments with
EGFP site #1, #2, #3, and #4, respectively. Two days following transfection, cells were
trypsinized and resuspended in Dulbecco's modified Eagle medium (DMEM, Invitrogen)
supplemented with 10% (vol/vol) fetal bovine serum (FBS) and analyzed on a BD LSRII
flow cytometer. For each sample, transfections and flow cytometry measurements were
performed in duplicate.
Transfection of human cells and isolation of genomic DNA
To assess the on-target and off-target indel mutations induced by RGNs targeted to
endogenous human genes, we transfected plasmids into U2OS.EGFP or FT-HEK293 (Life
Technologies) cells using the following conditions: U2OS.EGFP cells were transfected
using the same conditions as for the EGFP disruption assay described above. FT-HEK293
cells were transfected by seeding them at a density of 1.65 × 105 cells per well in 24 well
plates in Advanced DMEM (Life Technologies) supplemented with 10% FBS and 2 mM
GlutaMax (Life Technologies) at 37°C in a CO2 incubator. After 22 – 24 hours of
incubation, cells were transfected with 125 ng of gRNA expression plasmid or an empty U6
promoter plasmid (as a negative control), 375 ng of Cas9 expression plasmid (pJDS246)4,
and 10 ng of a td-Tomato expression plasmid, using Lipofectamine LTX reagent according
to the manufacturer's instructions (Life Technologies). Medium was changed 16 hours after
transfection. For both types of cells, genomic DNA was harvested two days post-
transfection using an Agencourt DNAdvance genomic DNA isolation kit (Beckman)
according to the manufacturer's instructions. For each RGN sample to be assayed, we
performed 12 individual 4D transfection replicates, isolated genomic DNA from each of
these 12 transfections, and then combined these samples to create two “duplicate” pools
each consisting of six pooled genomic DNA samples. We then assessed indel mutations at
on-target and off-target sites from these duplicate samples by T7EI assay, Sanger
sequencing, and/or deep sequencing as described below.
To assess frequencies of precise alterations introduced by HDR with ssODN donor
templates, 2×105 U2OS.EGFP cells were transfected 250 ng of gRNA expression plasmid or
an empty U6 promoter plasmid (as a negative control), 750 ng Cas9 expression plasmid
(pJDS246), 50 pmol of ssODN donor (or no ssODN for controls), and 10 ng of td-Tomato
expression plasmid (as the transfection control). Genomic DNA was purified three days after
transfection using Agencourt DNAdvance and assayed for the introduction of a BamHI site
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tat the locus of interest as described below. All of these transfections were performed in
duplicate.
For experiments involving Cas9 nickases, 2 × 105 U2OS.EGFP cells were transfected with
125 ng of each gRNA expression plasmid (if using paired gRNAs) or 250 ng of gRNA
expression plasmid (if using a single gRNA), 750 ng of Cas9-D10A nickase expression
plasmid (pJDS271), 10 ng of td-Tomato plasmid, and (if performing HDR) 50 pmol of
ssODN donor template (encoding the BamHI site). All transfections were performed in
duplicate. Genomic DNA harvested two days after transfection (if assaying for indel
mutations) or three days after transfection (if assaying for HDR/ssODN-mediated
alterations) using the Agencourt DNAdvance genomic DNA isolation kit (Beckman).
U2OS.EGFP and FT-HEK293 cell lines used in this study were tested for mycoplasma
contamination every two weeks.
T7EI assays for quantifying frequencies of indel mutations
T7EI assays were performed as previously described4. In brief, PCR reactions to amplify
specific on-target or off-target sites were performed with Phusion high-fidelity DNA
polymerase (New England Biolabs) using one of the two following programs: (1)
Touchdown PCR program [(98°C, 10 s; 72–62°C, −1 °C/cycle, 15 s; 72°C, 30 s) × 10
cycles, (98°C, 10 s; 62°C, 15 s; 72°C, 30 s) × 25 cycles] or (2) Constant Tm PCR program
[(98°C, 10 s; 68°C or 72°C, 15 s; 72°C, 30 s) × 35 cycles], with 3% DMSO or 1 M betaine if
necessary. All primers used for these amplifications are listed in Supplementary Table 8.
Resulting PCR products ranged in size from 300 to 800 bps and were purified by Ampure
XP beads (Agencourt) according to the manufacturer's instructions. 200ng of purified PCR
products were hybridized in 1 × NEB buffer 2 in a total volume of 19 μl and denatured to
form heteroduplexes using the following conditions: 95 °C, 5 minutes; 95 to 85 °C, −2 °C/s;
85 to 25 °C, −0.1 °C/s; hold at 4 °C. 1 μl of T7 Endonuclease I (New England Biolabs, 10
units/μl) was added to the hybridized PCR products and incubated at 37°C for 15 minutes.
The T7EI reaction was stopped by adding 2 μl of 0.25 M EDTA solution and the reaction
products were purified using AMPure XP beads (Agencourt) with elution in 20 μl 0.1× EB
buffer (QIAgen). Reactions products were then analyzed on a QIAXCEL capillary
electrophoresis system and the frequencies of indel mutations were calculated using the
same formula as previously described22. A more detailed protocol for the T7EI assay and
examples of sample capillary electrophoresis traces has been previously described22.
Sanger sequencing for quantifying frequencies of indel mutations
Purified PCR products used for T7EI assay were ligated into a Zero Blunt TOPO vector
(Life Technologies) and transformed into chemically competent Top 10 bacterial cells.
Plasmid DNAs were isolated and sequenced by the Massachusetts General Hospital (MGH)
DNA Automation Core, using an M13 forward primer (5'-GTAAAACGACGGCCAG-3').
Restriction digest assay for quantifying specific alterations induced by HDR with ssODNs
PCR reactions of specific on-target sites were performed using Phusion high-fidelity DNA
polymerase (New England Biolabs). The VEGFA and EMX1 loci were amplified using a
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ttouchdown PCR program ((98 °C, 10 s; 72–62 °C, −1 °C/cycle, 15 s; 72 °C, 30 s) × 10
cycles, (98 °C, 10 s; 62 °C, 15 s; 72 °C, 30 s) × 25 cycles), with 3% DMSO. The primers
used for these PCR reactions are listed in Supplementary Table 8. PCR products were
purified by Ampure XP beads (Agencourt) according to the manufacturer's instructions. For
detection of the BamHI restriction site encoded by the ssODN donor template, 200 ng of
purified PCR products were digested with BamHI at 37 °C for 45 minutes. The digested
products were purified by Ampure XP beads (Agencourt), eluted in 20ul 0.1×EB buffer and
analyzed and quantified using a QIAXCEL capillary electrophoresis system.
TruSeq library generation and sequencing data analysis
Locus-specific primers were designed to flank on-target and potential and verified off-target
sites to produce PCR products ~300bp to 400 bps in length. Genomic DNAs from the
pooled duplicate samples described above were used as templates for PCR. All PCR
products were purified by Ampure XP beads (Agencourt) per the manufacturer's
instructions. Purified PCR products were quantified on a QIAXCEL capillary
electrophoresis system. PCR products for each locus were amplified from each of the pooled
duplicate samples (described above), purified, quantified, and then pooled together in equal
quantities for deep sequencing. Pooled amplicons were ligated with dual-indexed Illumina
TruSeq adaptors as previously described29. The libraries were purified and run on a
QIAXCEL capillary electrophoresis system to verify change in size following adaptor
ligation. The adapter-ligated libraries were quantified by qPCR and then sequenced using
Illumina MiSeq 250 bp paired-end reads performed by the Dana-Farber Cancer Institute
Molecular Biology Core Facilities. We analyzed between 75,000 and 1,270,000 (average
~422,000) reads for each sample. The TruSeq reads were analyzed for rates of indel
mutagenesis as previously described30. Specificity ratios were calculated as the ratio of
observed mutagenesis at an on-target locus to that of a particular off-target locus as
determined by deep sequencing. Fold-improvements in specificity with tru-RGNs for
individual off-target sites were calculated as the specificity ratio observed with tru-gRNAs
to the specificity ratio for that same target with the matched full-length gRNA. As
mentioned in the text, for two of the known off-target sites, no indel mutations were detected
with tru-gRNAs. For these particular sites, it was difficult to quantify the on-target to off-
target ratios for tru-RGNs and, therefore, also the magnitude of improved specificity for tru-
RGNs to standard RGNs. For example, we did not observe any tru-RGN-induced indels at
sites OT1–4 and OT1–11 and thus the ratio of on-target to off-target rates would calculate to
be infinite in these cases. For these sites, we reasoned it was possible that the true rates
could be below the detection limit of our assay. Using the following equation, we calculated
that we would have a 95% probability of observing 1 or more mutagenesis events if the
mean number of mutagenesis events was 3:
Therefore, we used 3 as a conservative estimate of the number of events (instead of the 0
observed) as the numerator to estimate a lower bound for the fold-improvement of the tru-
gRNA in place of infinite improvement suggested by observing 0 events. All sequencing
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tdata has been deposited with National Center for Biotechnology Information Sequence Read
Archive (NCBI SRA), accession number SRP033215.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. On-target genome editing activities of truncated gRNAs and Cas9 nuclease in human
cells
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t(a) Target site in the EGFP gene used to assess the activities of gRNAs that are truncated at
their 5' end. Note that Gs near the 5' end (underlined) enable gRNAs with complementarity
lengths of 15, 17, 19 and 20 nt to be expressed from a U6 promoter in human cells. The
degenerate base of the protospacer adjacent motif (PAM) sequence (in this case, a C
nucleotide) is shown in lowercase.
(b) Efficiencies of EGFP disruption in human cells mediated by Cas9 and gRNAs bearing
variable length complementarity regions (shown in nts) for the target site of (a). Ctrl =
control gRNA lacking a complementarity region. Error bars indicate standard errors of the
mean (s.e.m.), n = 2.
(c) Efficiencies of EGFP disruption in human cells mediated by Cas9 and full-length or
shortened gRNAs for four target sites in the EGFP reporter gene (sites #1 – #4). Lengths
and sequences of the gRNA complementarity regions are shown. Ctrl, control gRNA lacking
a complementarity region; nt, nucleotides. Error bars represent s.e.m., n = 2.
(d) Efficiencies of targeted indel mutations introduced at seven different human endogenous
gene targets by matched standard and tru-RGNs. Lengths and sequences of gRNA
complementarity regions are shown. Indel frequencies were measured by T7EI assay. Ctrl =
control gRNA lacking a complementarity region. Three of the target sites used are named as
previously described4: VEGFA site 1 (aka Target site 1), VEGFA Site 3 (aka Target Site 3),
and EMX1 Site 1 (aka Target Site 4). VEGFA= vascular endothelial growth factor A,
EMX1= empty spiracles homolog 1. Error bars represent s.e.m., n = 2.
(e) Efficiencies of precise alterations mediated by homology-directed repair (HDR) using
single strand oligonucleotides (ssODN) at two endogenous human genes (VEGFA and
EMX1) with either full-length RGNs or tru-RGNs. The percentage of alleles in which HDR
had occurred (Percentage HDR) was measured using a BamHI restriction digest assay
(Online Methods). Control gRNA = control gRNA lacking a complementarity region. Error
bars represent s.e.m., n = 2.
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tFigure 2. tru-gRNAs exhibit enhanced specificities and function efficiently with Cas9 nuclease
and paired Cas9 nickases in human cells
(a) Activities of RGNs targeted to three sites in EGFP using full-length (top) or tru-gRNAs
(bottom) with single mismatches at each position (except at the 5'-most base which must
remain a G for efficient expression from the U6 promoter). Grey boxes in the grids show the
positions of Watson-Crick transversion mismatches. Empty gRNA control is a gRNA
lacking a complementarity region. RGN activities were measured using the EGFP disruption
assay and values shown represent the percentage of EGFP-negative observed relative to an
RGN using a perfectly matched gRNA. Experiments were performed in duplicate and means
with error bars representing s.e.m. are shown. Nucleotides present at each position of the
gRNA complementarity region are shown at the bottom of each panel.
(b) Activities of RGNs targeted to three sites in EGFP using full-length (top) or tru-gRNAs
(bottom) with adjacent double mismatches at each position (except at the 5'-most base which
must remain a G for efficient expression from the U6 promoter). Data presented as in (a).
(c) The percentage of sequencing reads containing on- and off-target indel mutations
induced by RGNs targeted to three different endogenous human gene sites as measured by
deep sequencing. Indel frequencies are shown for the three target sites from cells in which
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ttargeted RGNs with a full-length gRNA, a tru-gRNA, or a control gRNA lacking a
complementarity region were expressed. Sequences of the on-target and off-target (OT) sites
for full-length and tru-gRNAs are shown in Table 1. The scale of the y-axis is the same for
all three panels. Absolute counts of indel mutation data used to make these graphs can be
found in Supplementary Table 2. On-target sites are named as previously described4 and as
in Fig. 1d.
(d) Fold-improvements in off-target site specificities of three tru-RGNs compared to
matched standard RGNs. Values shown represent the ratio of on-target to off-target
activities for tru-RGNs divided by the ratio of on-target to off-target activities of standard
RGNs for the off-target sites shown, calculated using the data from (c) and Supplementary
Table 2. For the sites marked with an asterisk (*), no indels were observed with the tru-RGN
and therefore the values shown represent conservative statistical estimates for the fold-
improvements in specificities for these off-target sites (see Online Methods).
(e) Schematic illustrating locations of VEGFA sites 1 and 4 targeted by gRNAs and variant
Cas9 nickases to generate paired double nicks. Target sites for the full-length gRNAs are
underlined, with the first base in the PAM sequence shown in lowercase. Location of the
BamHI restriction site inserted by homology-directed repair (HDR) with a ssODN donor is
shown.
(f) Substitution of a full-length gRNA for VEGFA site 1 with a tru-gRNA does not reduce
the efficiency of indel mutations observed with a paired full-length gRNA for VEGFA site 4
and Cas9-D10A nickases. Control gRNA used is one lacking a complementarity region. The
frequency of indel mutations induced by the VEGFA site 4 gRNA alone with Cas9 nickase is
highlighted in red.
(g) Substitution of a full-length gRNA for VEGFA site 1 with a tru-gRNA does not reduce
the efficiency of BamHI sequence alterations introduced with a paired full-length gRNA for
VEGFA site 4, Cas9-D10A nickase, and an ssODN donor template. Control gRNA used is
one lacking a complementarity region.
Fu et al. Page 17
Nat Biotechnol. Author manuscript; available in PMC 2014 September 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tN
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Fu et al. Page 18
Table 1
Frequencies of indels induced at on- and off-target sites by tru-RGNs and matched standard RGNs in human
U2OS.EGFP cells
Target ID Gene Full-Length Target (20 nt) Indel mutation
frequency (%) Truncated Target (17 or 18 nts) Indel mutation
frequency (%)
Target Site 1 VEGFA GGGTGGGGGGAGTTTGCTCCtGG 23.69 [25.68, 21.70] GTGGGGGGAGTTTGCTCCtGG 23.93 [28.30, 19.55]
OT1–3 IGDCC3 GGATGGAGGGAGTTTGCTCCtGG 17.25 [20.22, 14.28] ATGGAGGGAGTTTGCTCCtGG Not Detected
OT1–4 LOC116437 GGGAGGGTGGAGTTTGCTCCtGG 6.23 [6.44, 6.03] GAGGGTGGAGTTTGCTCCtGG Not Detected
OT1–6 CACNA2D CGGGGGAGGGAGTTTGCTCCtGG 3.73 [3.95, 3.50] GGGGAGGGAGTTTGCTCCtGG Not Detected
OT1–11 GGGGAGGGGAAGTTTGCTCCtGG 10.36 [11.02, 9.69] GGAGGGGAAGTTTGCTCCtGG Not Detected
Target Site 3 VEGFA GGTGAGTGAGTGTGTGCGTGtGG 54.08 [55.10, 53.06] GAGTGAGTGTGTGCGTGtGG 50.49 [49.24, 51.74]
OT3–1 (abParts) GGTGAGTGAGTGTGTGTGTGaGG 6.16 [6.71, 5.60] GAGTGAGTGTGTGTGTGaGG Not Detected
OT3–2 MAX AGTGAGTGAGTGTGTGTGTGgGG 19.64 [18.58, 20.70] GAGTGAGTGTGTGTGTGgGG 5.52 [5.77, 5.27]
OT3–4 GCTGAGTGAGTGTATGCGTGtGG 7.95 [7.84, 8.06] GAGTGAGTGTATGCGTGtGG 1.69 [1.42, 1.95]
OT3–9 TPCN2 GGTGAGTGAGTGCGTGCGGGtGG Not Detected GAGTGAGTGCGTGCGGGtGG Not Detected
OT3–17 SLIT1 GTTGAGTGAATGTGTGCGTGaGG 1.85 [1.77, 1.92] GAGTGAATGTGTGCGTGaGG Not Detected
OT3–18 COMDA TGTGGGTGAGTGTGTGCGTGaGG 6.16 [6.72, 5.60] GGGTGAGTGTGTGCGTGaGG Not Detected
OT3–20 AGAGAGTGAGTGTGTGCATGaGG 10.47 [9.39, 11.55] GAGTGAGTGTGTGCATGaGG Not Detected
Target Site 4 EMX1 GAGTCCGAGCAGAAGAAGAAgGG 41.56 [41.76, 41.37] GTCCGAGCAGAAGAAGAAgGG 43.01 [43.89, 42.15]
OT4–1 HCN1 GAGTTAGAGCAGAAGAAGAAaGG 19.26 [18.54, 19.99] GTTAGAGCAGAAGAAGAAaGG Not Detected
OT4_53* MFAP1 GAGTCTAAGCAGAAGAAGAAgAG 4.37 [3.79, 4.96] GTCTAAGCAGAAGAAGAAgAG Not Detected
Mutation frequencies were assessed by T7EI assay with means (bold text) of duplicate measurements (in brackets) shown.
*
Off-target site OT4_53 is the same as EMX1 target 3 OT31 from ref. 5.
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